Einzigartige Einblicke aus mehreren NASH-Studien
Related insights
More from our insights
Development pathways and trial design for liver cirrhosis secondary to NASH
Download White PaperGet Your Study Enrolled - Designing Your Impairment Protocol to Prevent Challenges
Webinar ansehenEinzigartige Partnerschaften zur Erforschung seltener Nierenerkrankungen
Explore Fortrea's unique collaborative efforts in researching and addressing rare kidney diseases through advanced methodologies and patient-centric approaches.
WeiterlesenSGLT2-Inhibitoren als nierenschützende Agenten für pädiatrische Patienten mit chronischen Nierenerkrankungen
Explore the benefits of SGLT2 inhibitors as renoprotective agents for pediatric patients. Fortrea's blog provides insights into diabetes medication and renal protection.
WeiterlesenUnleashing the power of data sharing to transform the drug development landscape for kidney diseases
In 2016, Barbara Gillespie, MD, FASN, Vice President and Therapeutic Head of Nephrology at Fortrea, joined a workgroup with the Kidney Health Initiative (KHI) and U.S. FDA. T
Download ArticleAnmeldung Ihrer Studie – Welche Angaben Sie in dem Protokoll zu Ihrer Studie zu Niereninsuffizienz vermeiden müssen, um eine Verlangsamung der Anwerbung zu verhindern
Webinar ansehenDr. Gillespie goes to Capitol Hill to advocate for rare kidney disease
Dr. Barbara Gillespie, Vice President & Therapeutic Strategy Leader at Fortrea, recently participated in “Rare Kidneys on the Hill Day” on July 25th, joining patients, caregivers, physicians and researchers on Capitol Hill to speak with members of Congress and raise awareness about rare kidney disease (RKD).
WeiterlesenVerbinden Sie sich mit uns
We've been driving innovation with our tailored clinical solutions for 30+ years. Let's connect.